UTHRUnited Therapeutics Corporation
Is the price fair?
Neither cheap nor expensive: modest expectations priced in and cheap vs its sector, but at the top of its own P/E range.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 14% a year, expectations look modest.
Expensive vs its own history: P/E 19.7 vs a 12.5 median over 37 quarters (+57% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What UTHR's price assumes
United Therapeutics Corporation trades at 19.7× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · cheaper than the typical name in its group
- Price / sales
- 7.25
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 4.7%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +6.4%
Growth the price implies · The price pays for +6.4% free cash flow growth a year for a decade; the business has delivered +18% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 3.25
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 13.5
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 6.33
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $1.09B
- Market capitalisation
- $23.1B
- 3-year revenue growth
- +14%
- 3-year free cash flow growth
- +18%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $288.14 |
| Its own P/E history, median | $349.25 |
| Its own P/E history, upper quartile | $443.50 |
| 52-week range | $414.73 – $596.76 |
| Today | $549.48 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #2 of 41 by RyuScore